knowledge -WSS

knowledge

author：hotspot 2025-09-28 21:04:16 - browse：88859

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Brain injuries and the importance of a second opinion

WSS

Steward Health Care expansion into Malta flopped

6 surprising facts about sugar

'Patient friction coefficient' can gauge a clinical trial's patient burden

Yancopoulos of Regeneron works to expand Dupixent success

Testing GLP

Cancer, immunology, HIV research ensnared in fetal tissue politics

Wikipedia

knowledge

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Malaria cases in Florida and Texas: Here’s what you need to know

Testing GLP

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bill would allow buprenorphine prescription for addiction via telehealth

Activists slam private health insurers over coverage restrictions

Mirador, a new biotech startup, launches with $400 million

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Inari Medical to buy amputation prevention company LimFlow

entertainment

Medicare must police algorithms in Medicare Advantage, Dems say

Medicare must police algorithms in Medicare Advantage, Dems say

Medicare must police algorithms in Medicare Advantage, Dems say

U.K. officials, researchers try to ease path for bespoke genetic treatments

Asbestos ban is immediate, but health effects will linger for decades

Kidney transplant patients stopped immunosuppressants in trial

hotspot

hotspot

Wikipedia

leisure time